title: First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
authors.affiliation: Department of Neurology, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden, clas.malmestrom@neuro.gu.se.
authors.forename: Clas
authors.initials: C
authors.lastname: Malmeström
authors.forename: Bengt A
authors.initials: BA
authors.lastname: Andersson
authors.forename: Jan
authors.initials: J
authors.lastname: Lycke
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001323:Autoantibodies / Q000097:blood; D003920:Diabetes Mellitus / Q000503:physiopathology*; D005260:Female; D006111:Graves Disease / Q000139:chemically induced*; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001323:Autoantibodies; D000074323:Alemtuzumab
references.citation: Ann N Y Acad Sci. 2013 Apr;1281:1-15
references.pmid: 23360422
references.citation: Lancet. 2012 Nov 24;380(9856):1819-28
references.pmid: 23122652
references.citation: Diabetes Care. 2010 Jun;33(6):1206-12
references.pmid: 20508230
references.citation: Immunity. 2010 Apr 23;32(4):457-67
references.pmid: 20412756
references.citation: Neurology. 2011 Aug 9;77(6):573-9
references.pmid: 21795656
references.citation: Lancet. 2012 Nov 24;380(9856):1829-39
references.pmid: 23122650
references.citation: Transl Res. 2014 Aug;164(2):110-21
references.pmid: 24662515
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5
references.pmid: 17942684
references.citation: Immunity. 2010 Apr 23;32(4):468-78
references.pmid: 20412757